We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-14.00 | -0.12% | 12,096.00 | 12,086.00 | 12,092.00 | 12,118.00 | 12,038.00 | 12,090.00 | 1,525,268 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.47 | 187.42B |
Date | Subject | Author | Discuss |
---|---|---|---|
20/12/2020 17:28 | Oxford coronavirus vaccine approval expected shortly after Christmas,government sources claim A vaccine a developed by the University of Oxford is set to be approved within days of Christmas, according to senior Whitehall sources. The Medicines and Healthcare Regulatory Agency (MHRA) is believed to be set to authorise the vaccines on December 28 or 29 after final data is provided to the regulator on Monday... www.independent.co.u | bountyhunter | |
20/12/2020 13:56 | It won't get approval in US, I reckon, they will want more data. U.K. seems desperate they will pass. | montyhedge | |
19/12/2020 19:01 | The Oxford/AstraZeneca coronavirus vaccine is still being reviewed, the UK’s medicine agency has said, amid reports that doses could be ready by 28 December. It is thought that the Medicines and Healthcare products Regulatory Agency (MHRA) will give the vaccine the green light at some point during the week of 28 December, triggering its immediate rollout by the NHS. But Whitehall sources said that while they hoped the vaccine would be available that week, it was by no means certain, and the authorisation could be delayed until the beginning of January. The delay has caused frustration in Whitehall and the NHS, with the vaccine taking much longer to meet approval than the Pfizer vaccine, which was rolled out in the UK last week. | philanderer | |
19/12/2020 13:09 | Vaccine to be approved 28th 29th December. It will make for a merry new year folks | bogman1 | |
18/12/2020 22:26 | And they have also bought the expertise to work on a new pipeline | bogman1 | |
18/12/2020 20:39 | I would assume AZN management remembered to check patent expiration dates before they launched the bid ?? | smcni1968 | |
18/12/2020 18:35 | buywell notes others are belatedly talking about the generic problem buywell314 Dec '20 - 18:35 - 3384 of 3429 Edit These are already dire Loads of negative values due to HUGE NET DEBT buying Blockbuster expensive drugs for large monies is all to do with how long the IP lasts in terms of protection and exclusivity of markets Once that goes the generics come along | buywell3 | |
18/12/2020 12:40 | From the RNS...Soliris's patent protection is waning, and the drug faces potential competition that could undercut sales. In June, Alexion reached a legal settlement with Amgen Inc. to delay its launch of a copycat drug until 2025.The delay gives Alexion crucial breathing room to persuade doctors to switch their patients onto a new drug called Ultomiris that is protected from U.S. competition until at least 2030. | gregb | |
18/12/2020 11:16 | "ahead of generic competition" That surprised me with the post. I would have thought that at that price there would be very long IP. | alphorn | |
18/12/2020 11:06 | Liberum alert to AstraZeneca-Alexion bid risks AstraZeneca’s (AZN) $37bn acquisition of US rare disease specialist Alexion (ALXN.O) works financially but Liberum says there are ‘some risks’. Analyst Alistair Campbell retained his ‘buy’ recommendation on the stock but reduced his target price from £97.70 to £94.30. The shares fell 1.2% to £75.50 yesterday. ‘The deal works from a financial point of view, with low teens earnings per share accretion and a positive uplift to our discounted cashflow,’ he said. ‘However, there are some risks. Alexion needs to switch its lead drug into its second generation product ahead of generic competition, and there’s some risk of a counterbid forcing the deal value upwards.’ However, Campbell said he had reset his forecasts on the assumption the deal would complete. | philanderer | |
18/12/2020 08:59 | Three director buys in the last few days. Not insignificant amounts either - two of them each bought £100,000 worth. | bluemango | |
18/12/2020 00:22 | 2021 will see ‘vaccine cooperation, not competition,’ Russian official says after AstraZeneca tie-up | philanderer | |
17/12/2020 11:44 | I go with the 6700p. | montyhedge | |
17/12/2020 11:27 | Single targeted mRNA Vaccines for single Covi-19 strain. Now there are 4 strains. | ftse100djia | |
17/12/2020 11:23 | Take your pick ;-) 17th dec Liberum buy tp 9430p 17th dec DZ Bank sell tp 6700p | philanderer | |
17/12/2020 00:47 | U.K. Hopes Oxford-Astra Vaccine Will Be Ready by Early New Year | philanderer | |
16/12/2020 13:59 | Rebounding nicely | smcni1968 | |
16/12/2020 08:26 | Prefer GSK 5.9% yield over Astra's at the moment. | montyhedge | |
15/12/2020 23:45 | You're the Professor ... | smcni1968 | |
15/12/2020 21:28 | How can i buy this share | professor_peaky | |
15/12/2020 19:31 | Astra and GSK both down 2.4% today | smcni1968 | |
15/12/2020 19:06 | AZN threw quite a lot of news at the markets over the last couple of days imo to try to keep the share price at levels that helped the bid for Alexion buywell wonders how much more positive newsflow azn has left in the locker that can now counteract market sentiment buywell is still of the opinion that investors in the USA will have to come to terms with reality of the Global Downturn taking place and Covid-19 continuance Stimulus packages forever otherwise in a Covid-19 endemic Other actions needed see BUY Mass Testing has caused Politicians to NOT carry out National Lockdowns as it has fudged the issue with false hopes as has masks and track and trace Lack of National Lockdowns of at least 8 weeks duration or better still 12 weeks Has caused the worldwide mess we are now in ---- and getting worse buy the day Germany is locking down till Jan 10th ie not enough like Holland and the Czech Republic Italy will act later this week or else go into meltdown | buywell3 | |
15/12/2020 19:05 | buywell, remind me what that was ? thanks | philanderer | |
15/12/2020 18:55 | Not true --- you bought a stock buywell recommended on NFDS but have recently sold Well done buy the way u must have done well philanderer 14 Dec '20 - 20:11 - 3389 of 3412 0 1 0 matt, I'm not expecting one, I've tried a couple of times before and got blanked ;-) | buywell3 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions